Genprex

Tagged: Guidance

Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck

AUSTIN, Texas & CAMBRIDGE, Mass.— (September 3, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex™ immunogene therapy, to market.

These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found on the company’s website….

Read More